Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy

Abstract EN

Glioblastoma (GBM) is the most lethal primary brain tumor, and despite several refinements in its multimodal management, generally has very poor prognosis.

Targeted immunotherapy is an emerging field of research that shows great promise in the treatment of GBM.

One of the most extensively studied targets is the interleukin-13 receptor alpha chain variant 2 (IL13Rα2).

Its selective expression on GBM, discovered almost two decades ago, has been a target for therapy ever since.

Immunotherapeutic strategies have been developed targeting IL13Rα2, including monoclonal antibodies as well as cell-based strategies such as IL13Rα2-pulsed dendritic cells and IL13Rα2-targeted chimeric antigen receptor-expressing T cells.

Advanced therapeutic development has led to the completion of several clinical trials with promising outcomes.

In this review, we will discuss the recent advances in the IL13Rα2-targeted immunotherapy and evaluate the most promising strategy for targeted GBM immunotherapy.